Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.
A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that the reason for this is in part due to the patient's own immune system, which quickly works to eliminate the anticancer virus.
The findings, published in the journal Nature Medicine, show that the body responds to the anticancer virus as it does to an infection. Within hours, specialized immune cells called natural killer (NK) cells move in to eliminate the therapeutic virus in the brain.
The researchers discovered that the NK cells attack the viruses when they express specific molecules on their surface called NKp30 and NKp46. "These receptor molecules enable the NK cells to recognize and destroy the anticancer viruses before the viruses can destroy the tumor," says co-senior author Dr. Michael A. Caligiuri, director of Ohio State's Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute, and a senior author of the study.
"When we blocked those receptors, the virus has more time to work, and mice with these brain tumors live longer. The next step is to block these molecules on NK cells in glioblastoma patients and see if we can improve their outcome," says Caligiuri, who is also the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. This study of cancer-cell-killing, or oncolytic, viruses is an example of the value of translational research, in which a problem observed during clinical trials is studied in the laboratory to devise a solution.
"In this case, clinical trials of oncolytic viruses proved safe for use in the brain, but we noticed substantial numbers of immune cells in brain tumors after treatment," says senior author and neurosurgeon Dr. E. Antonio Chiocca, who was professor and chair of neurological surgery while at Ohio State University.
"To understand this process, we went back to the laboratory and showed that NK cells rapidly infiltrate tumors in mice that have been treated with the therapeutic virus. These NK cells also signal other inflammatory cells to come in and destroy the cancer-killing virus in the tumor."
The study used an oncolytic herpes simplex virus, human glioblastoma tumor tissue and mouse models, one of which hosted both human glioblastoma cells and human NK cells. Key technical findings include:
"Once we identify the molecules on glioblastoma cells that these NK cell receptors bind with, we might be able to use them to identify patients who will be sensitive to this therapy," Caligiuri says.
Ohio State University Medical Center: http://medicalcenter.osu.edu/Pages/index.aspx
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
When you're paid to hit people, it's not always easy to stop at the end of the work day—a fact the NFL has to reckon with, and fast
Is Democracy a key to better levels of health in a country? That's long been the belief, but we hear about some research that shows that isn't always the case.
You can learn a lot about people if you mess with their minds. Here are four infamous experiments in which psychologists gave in to unethical temptations
The number of people without enough to eat has fallen rapidly over the past 25 years, but sub-Saharan Africa and parts of Asia are still struggling
New research raises serious questions about how artificial sweeteners might affect our bodies, but let's keep our cool and just do more research
Do you want to be a lab rat? That's what teenagers are doing when they smoke marijuana, the state of Colorado says. But since hard evidence of marijuana's harms is scanty, it may be a tough sell.
Caitlin Doughty has been cutting pacemakers out of corpses, grinding human bones by hand, and loading bodies into cremation chambers for seven years. But the 30-year-old mortician doesn't want to keep all the fun to herself: She thinks the rest of us should get to have a little more face time with the deceased.
A trial of an experimental vaccine against the Ebola virus is to begin in Oxford.
A simple urine test for the virus that causes cervical cancer could offer a less invasive and more acceptable alternative to the conventional cervical smear test, researchers said on Tuesday.
President Barack Obama and U.S. Senate commit to help West Africa wallop the virus